contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pledpharma-receives-us-patent-for-method-of-treatment-related-to-calmangafodipir

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Egetis Therapeutics

PledPharma AB (STO: PLED) has received a notice of allowance from US Patent Office (USPTO) regarding method of treatment claims, forming an additional protective layer around candidate drugs...

<div class="mfn-preamble"><p><strong>PledPharma AB (STO: PLED) has received a notice of allowance from US Patent Office (USPTO) regarding method of treatment claims, forming an additional protective layer around candidate drugs PledOx® and Aladote®.</strong></p></div><div class="mfn-body"><p>The decision from USPTO is based on PledPharma’s second patent application with the title ”Pharmaceutical Compositions and Therapeutic Methods Employing a Combination of a Manganese Complex Compound and a Non-Manganese Complex Form of the Compound”. The expiry date for the patent is July 2030.</p><p>“We are pleased with the notice of allowance of our second patent application from the USPTO to further strengthen our robust patent portfolio”, said Nicklas Westerholm, CEO, PledPharma.</p><p>This second patent family protects against the use of a manganese-containing complex (e.g. mangafodipir) in combination or administered sequentially with a non-manganese complex (e.g. calcium fodipir), This is in addition to the already approved composition-of-matter patent of calmangafodipir for the treatment of e.g. acetaminophen (paracetamol) induced acute liver failure or oxaliplatin induced peripheral nerve damage, with expiry date December 2032.</p><p>The patent has previously been approved in Australia, Canada, Europe, India, Israel, Japan, Mexico, Russia, South Africa and South Korea, with July 2030 as its expiry date.</p></div><div class="mfn-footer mfn-contacts"><p><strong>Contacts</strong></p><hr/><p>Nicklas Westerholm, CEO, phone: +46 73 354 20 62 <br/><a href="mailto:nicklas.westerholm@pledpharma.se" target="_blank" rel="nofollow noopener">nicklas.westerholm@pledpharma.se</a> <br/> <br/>Yilmaz Mahshid, CFO, phone: +46 72 231 68 00 <br/><a href="mailto:yilmaz.mahshid@pledpharma.se" target="_blank" rel="nofollow noopener">yilmaz.mahshid@pledpharma.se</a></p></div><div class="mfn-footer mfn-about"><p><strong class="mfn-heading-1">About Us</strong></p><hr/><p>PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project <strong>PledOx®</strong> is being developed to reduce nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020. The drug candidate <strong>Aladote®</strong> is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see <a href="http://www.pledpharma.com/" target="_blank" rel="nofollow noopener">http://www.pledpharma.com/</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-pdf"><p><strong class="mfn-heading-1">Attachments</strong></p><hr/><p><a href="https://storage.mfn.se/124809ab-98ad-4a3f-93e2-4b3295e51b05/patent-eng-final.pdf" target="_blank" class="mfn-primary" rel="nofollow noopener">Patent ENG Final</a></p></div>

PledPharma receives US patent for method of treatment related to calmangafodipir